WallStSmart

BP PLC ADR (BP)vsZepp Health Corp (ZEPP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

BP PLC ADR generates 80336% more annual revenue ($187.64B vs $233.27M). BP leads profitability with a 3.0% profit margin vs -28.3%. BP earns a higher WallStSmart Score of 54/100 (C-).

BP

Buy

54

out of 100

Grade: C-

Growth: 5.3Profit: 4.5Value: 4.7Quality: 5.0

ZEPP

Hold

38

out of 100

Grade: F

Growth: 4.7Profit: 2.0Value: 5.0Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BPSignificantly Overvalued (-4001.1%)

Margin of Safety

-4001.1%

Fair Value

$0.94

Current Price

$44.78

$43.84 premium

UndervaluedFair: $0.94Overvalued

Intrinsic value data unavailable for ZEPP.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BP4 strengths · Avg: 9.3/10
PEG RatioValuation
0.1810/10

Growing faster than its price suggests

EPS GrowthGrowth
500.0%10/10

Earnings expanding 500.0% YoY

Market CapQuality
$112.33B9/10

Large-cap with strong market position

Free Cash FlowQuality
$4.14B8/10

Generating 4.1B in free cash flow

ZEPP2 strengths · Avg: 10.0/10
Price/BookValuation
0.9x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
78.5%10/10

Revenue surging 78.5% year-over-year

Areas to Watch

BP4 concerns · Avg: 3.5/10
Price/BookValuation
13.0x4/10

Trading at 13.0x book value

Revenue GrowthGrowth
3.6%4/10

3.6% revenue growth

Return on EquityProfitability
1.7%3/10

ROE of 1.7% — below average capital efficiency

Profit MarginProfitability
3.0%3/10

3.0% margin — thin

ZEPP4 concerns · Avg: 2.0/10
Market CapQuality
$237.22M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-24.4%2/10

ROE of -24.4% — below average capital efficiency

EPS GrowthGrowth
-68.1%2/10

Earnings declined 68.1%

Profit MarginProfitability
-28.3%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : BP

The strongest argument for BP centers on PEG Ratio, EPS Growth, Market Cap. PEG of 0.18 suggests the stock is reasonably priced for its growth.

Bull Case : ZEPP

The strongest argument for ZEPP centers on Price/Book, Revenue Growth. Revenue growth of 78.5% demonstrates continued momentum.

Bear Case : BP

The primary concerns for BP are Price/Book, Revenue Growth, Return on Equity. A P/E of 2192.5x leaves little room for execution misses. Thin 3.0% margins leave little buffer for downturns.

Bear Case : ZEPP

The primary concerns for ZEPP are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

BP profiles as a value stock while ZEPP is a hypergrowth play — different risk/reward profiles.

ZEPP carries more volatility with a beta of 1.59 — expect wider price swings.

ZEPP is growing revenue faster at 78.5% — sustainability is the question.

Monitor OIL & GAS INTEGRATED industry trends, competitive dynamics, and regulatory changes.

Bottom Line

BP scores higher overall (54/100 vs 38/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

BP PLC ADR

ENERGY · OIL & GAS INTEGRATED · USA

BP plc participates in the energy business globally. The company is headquartered in London, the United Kingdom.

Zepp Health Corp

TECHNOLOGY · CONSUMER ELECTRONICS · China

Zepp Health Corporation, an activity and biometric data-driven company, develops, manufactures and sells smart wearable technology devices in the People's Republic of China. The company is headquartered in Hefei, the People's Republic of China.

Want to dig deeper into these stocks?